• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Discover Which Indications Have the Greatest Potential to Provide Franchise Growth and Understand the Growth Drivers of Major Classes of Women's Health Treatments

Posted on: Monday, 30 April 2007, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c55497) has announced the addition of "The Women's Health Market Outlook to 2011" to their offering.

With increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women's health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes.

'The Women's Health Market Outlook to 2011' is a new report providing analysis of the current and future market for women's health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women's health market. Key indications covered in this report are osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynaecological infections.

Key findings of this new report:

The leading hormonal contraceptive brand in 2005 was Schering AG's (now Bayer Schering Pharma) Yasmin which accrued $666m in sales. Schering has recently launched a low dose version of Yasmin,called Yaz which has been approved in the additional indications of acne and PMDD and is forecast to accrue $730m in sales by 2011.

Of the newly launched products that are considered to be associated with strong potential success, GSK's Boniva (ibandronate) indicated for the treatment of osteoporosis is forecast to accrue $1,309m by the end of the forecast period in 2011.

Although Merck held the leading position among competing companies in the WH market in 2005, its marketed franchise comprises of a lone product, Fosamax, with an indication in osteoporosis Fosamax and its reformulated counter part Fosamax PLUS D which accrued combined sales of $2,845m in 2005.

Your questions answered:

What indications are driving current growth in this therapeutic area?

What are the current trends within the major indications such as osteoporosis, urinary incontinence and sub indications of HRT?

How important are drug delivery and reformulation strategies to product innovation and life cycle strategies in this therapeutic area?

Which indications within this therapeutic market are forecast to benefit the most from new product development activity in the next few years?

Which indication is forecast to feature the strongest performance in terms of new sales from new launches by major pharmaceutical companies?

Which companies are best positioned for success in this therapeutic area and why?

This report will enable you to:

Quantify patient potential; assess treatment trends and sales patterns with this report's in-depth coverage of the major women's health indications.

Forecast sales of the major products in the women's health area over the period 2006-11 in major indications, classes of treatments and by company.

Evaluate how market share of leading companies, such as Merck, GlaxoSmithKline and Pfizer, will change over the next 6 years, and assess your competitive position within the market.

Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of women's health treatments.

Areas covered:

Epidemiology of Women's Health

Global market analysis

Pipeline analysis

Competitive landscape

For more information visit http://www.researchandmarkets.com/reports/c55497

Source: Business Insights

Source: Business Wire

More News in this Category